📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
3 articles
AVG GRADE
NEUTRAL
score: 0.17
SENTIMENT
NEUTRAL
TOTAL VIEWS
26
LEGN Latest News & AI Sentiment Analysis
3 articles · Grade: NEUTRAL · Real-time AI-graded coverage
RECENT COVERAGE · 10 ARTICLES
ADARx Pharmaceuticals Expands Leadership Team with Board and Executive Appointments
ADARx Pharmaceuticals announced organizational changes through board and executive leadership appointments, including Dr. Ying Huang...
Legend’s Pipeline Is Starting To Matter (NASDAQ:LEGN)
Legend Biotech (LEGN) is undergoing a significant operational inflection as it pivots from a cash-burn biotech model toward commercial...
Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript
Legend Biotech (LEGN) released its Q2 2026 earnings call transcript, a scheduled procedural disclosure that provides historical...
Leadership changes afoot at two CGT biotechs
Legend Biotech's unexpected CEO departure introduces leadership uncertainty that typically pressures stock valuations in the near term,...
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
Legend Biotech (LEGN) announced a scheduled earnings call for August 11, 2026, to discuss second-quarter 2026 financial performance....
Legend Biotech: Why I'm Ready To Go Long Again (NASDAQ:LEGN)
Legend Biotech (LEGN) has demonstrated meaningful commercial momentum in Q2, with Carvykti demand tracking ahead of initial expectations...
A New Look At Legend Biotech: Plenty Of Upside For Carvykti (NASDAQ:LEGN)
Legend Biotech (LEGN) is receiving analyst attention for its commercial pipeline centered on Carvykti, a CAR-T cell therapy designed for...
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
Calidi Biotherapeutics announced the appointment of Corsee Sanders, a veteran biotech executive with 30+ years at major pharmaceutical...
Legend Biotech Corporation Announces Proposed Public Offering
LEGN announced a $225 million underwritten public offering of American Depositary Shares, with underwriters granted a 30-day option to...
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Legend Biotech announced Phase 1 clinical proof-of-concept for LB2501, an in vivo dual-targeting CAR-T therapy designed to treat...
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice